There are still approximately 500 million cases of malaria and 1 million deaths from malaria
each year. Yet recently, malaria incidence has been dramatically reduced in some parts of …

Malaria, which is caused by Plasmodium spp., starts with an asymptomatic phase, during
which sporozoites, the parasite form that is injected into the skin by a mosquito, develop into …

For 50 years since their discovery, the malaria parasite liver stages (LS) have been difficult
to analyze, impeding their utilization as a critical target for antiinfection vaccines and drugs …

Malaria is a vector‐borne infectious disease caused by unicellular parasites of the genus
Plasmodium. These obligate intracellular parasites have the unique capacity to infect and …

The development of an effective malaria vaccine remains a global public health priority.
Less than 0.5% of the Plasmodium falciparum genome has been assessed as potential …

Falciparum malaria is initiated when Anopheles mosquitoes transmit the Plasmodium
sporozoite stage during a blood meal. Irradiated sporozoites confer sterile protection against …

Vaccination with infectious Plasmodium falciparum (Pf) sporozoites (SPZ) administered with
antimalarial drugs (PfSPZ-CVac), confers superior sterilizing protection against infection …

Live attenuated malaria vaccines are more potent than the recombinant protein, bacterial or
viral platform vaccines that have been tested, and an attenuated sporozoite vaccine against …

Plasmodium falciparum malaria still remains a major global public health challenge with
over 220 million new cases and well over 400,000 deaths annually. Most of the deaths occur …

Malaria remains the most prevalent vector-borne infectious disease and has the highest
rates of fatality. Current antimalarial drug strategies cure malaria or prevent infections but …